The CDC Recommends a New COVID-19 Vaccine Series

The United States Centers for Disease Control and Prevention released a statement on July 20 recommending the addition of the Novavax COVID-19 vaccine series to the current armamentarium of immunizations against SARS-CoV-2 among individuals ages 18 and older. The Novavax currently has Emergency Use Authorization from the US Food and Drug Administration. The vaccine was funded by the US Department of Defense and uses spike proteins and an immune-system stimulator to create an immune response to the novel coronavirus in recipients. A clinical trial of more than 29,000 subjects revealed the Novavax vaccine is both safe and effective. It is a two-dose vaccine with injections spaced 3 to 4 weeks apart. Click here to read more.